Total metabolic tumor volume on 18F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy
Purpose Because of atypical response imaging patterns in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs), new biomarkers are needed for a better monitoring of treatment efficacy. The aim of this prospective study was to evaluate the progn...
| المؤلفون الرئيسيون: | , , , , , , |
|---|---|
| التنسيق: | مقال |
| اللغة: | English |
| منشور في: |
BMJ Publishing Group
2024-04-01
|
| سلاسل: | Journal for ImmunoTherapy of Cancer |
| الوصول للمادة أونلاين: | https://jitc.bmj.com/content/12/4/e007628.full |